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Abstract
Vacuolar-proton translocating-ATPases (V-ATPases) are the membranebound transporters responsible for controlling pH levels in intracellular
compartments. The V-ATPase enzyme is a multi-subunit complex consisting of
two distinct domains, a cytosolic V1 region and a membrane-bound Vo domain.
While the interface between V1 and Vo is not as well understood, studies suggest
the possibility of multiple peripheral stalks tethering the complex. In response to
glucose deprivation, the V1 and Vo sectors of the enzyme are capable of
dissociating into separate, and inactive, domains as a means of regulation. At
least 4 V1 subunits (C, H, E, and G) are believed to form the peripheral stalk(s) of
the V-ATPase. Of considerable interest amongst peripheral stalk subunits has
been the H subunit, a protein which has been implicated in the suppression of VATPase activity in free V1 domains and also recently shown to play a key a role
in the structural and functional coupling of V1 to Vo.
In this study, we’ve identified a clear haploinsufficiency for the VMA13
gene (encoding subunit H). Initially manifested as a growth defect at elevated pH
and/or in the presence of extracellular calcium, haploinsufficiency of the VMA13
gene proved to have more profound biological implications on the cell, reducing
vacuolar acidification in vivo, ATPase activity at the vacuole, and allowing for
ATP hydrolysis in free V1 complexes in the cytoplasm. The importance of
VMA13 gene product as both a peripheral stalk protein and structural/functional
regulator of the enzyme led us to further investigate the biochemical basis of this
haploinsufficiency by selectively forming compound heterozygous mutants.
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After crossing vma13 mutants to various vma knockouts, we found altered
phenotypes of compound haploinsufficiencies for the enzyme. Creating an
imbalance of both subunits H (Vma13p) and c (Vma3p) exacerbated
haploinsufficiency phenotypes of cells, slowing growth on all media, eradicating
in vivo acidification at the vacuole, increasing cytosolic ATPase activity, and
reducing overall enzyme activity and assembly at the vacuolar membrane. In
contrast to these results, altering the balance of both H and B subunits (Vma13p
and Vma2p respectively), led to the opposite result.
Together, the subunit locations and phenotypes of compound
heterozygous vma mutants are explained, at least in part, by their biochemical
phenotypes. A perturbation of H subunit stoichioimetry creates a gain in ATPase
activity in the stable population of free V1 sectors in the cytoplasm and results in
an uncoupling of ATP hydrolysis and proton translocation, in essence wasting
away intracellular energy stores. The wasting of energy coincides with the poor
growth of vma13Δ heterozygotes and, along the same lines, the level and activity
of this active free V1 population underlies many phenotypic differences amongst
compound heterozygous mutants. While many compound mutant phenotypes can
be explained by this biochemical phenomenon, a reduction of ATPase activity at
the vacuole along with reduced V-ATPase assembly at the vacuole for some
strains (e.g. vma13Δ x vma3Δ heterozygotes) suggests that perturbation of certain
subunit levels may also have synergistic effects on overall enzyme stability and
assembly. In summary, this data sheds light onto subunits in the V-ATPase
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enzyme normally present, in vivo, in limited quantities, highlighting their
importance for an active and healthy enzyme.
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Advice for future honors students

For future honors students my advice is simple: study something you love. People
may committ to an endeavor of this capacity for many reasons, however without
both your head and your heart in that commitment, it will be one long haul.

To science majors: spend as much time in the lab as possible. Early laboratory
experience is priceless to a science major hoping to write a thesis. The more time
you spend in lab, the more you will learn through experience and the more
independence you will gain in your own research. Through this independence you
can ask more questions and find more answers, ultimatley giving you more data.

Also, put in extra time wherever possible. Work in lab over breaks, weekends, or
the summer. There are many research opportunities (and stipends) available to
support your endeavors and this will get you ahead of your classmates, even if
you’ve gotten a late start on your project. I’ve even bee in the lab overnight and
that helps too!

And just a few more suggestions:

Always work hard.
Always finish strong.
Best of luck!
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Introduction
Vacuolar-proton translocating-ATPases (V-ATPases) are the membranebound transporters responsible for controlling pH levels in intracellular
compartments. Given the vital role of organelle acidification in pH homeostasis
and cellular metabolism, a functional V-ATPase enzyme is essential for a variety
of intracellular processes including receptor-mediated endocytosis, protein
sorting, processing and degradation, targeting of lysosomal enzymes, and coupled
transport of molecules [1-3]. In addition to its role as a key intracellular agent, the
V-ATPase enzyme is also found at the plasma membranes of specialized cells
where it contributes to functions ranging from acid secretion and bone dissolution
to sperm motility and tumour metastasis [1, 3-6]. Currently, the V-ATPase
continues to be linked to a variety of novel functions, such as HIV entry into the
cell [7], and has become an increased focal point in the treatment and/or
identification of various genetic disorders in humans [8-10]. Together, the
versatility of organellar and plasma membrane V-ATPases testify to the enzyme’s
broad and evolving functionality.
As the story continues to be written for the V-ATPase enzyme, previous
findings coupled with future directions have already cemented the protontranslocator’s presence and importance in all eukaryotic systems to date. In all
cases, V-ATPases carry out the active transport of protons from a cytosolic
compartment to the opposite side of a membrane via a highly conserved structure
and mechanism [1-3]. The enzyme is organized as a multi-subunit complex
consisting of two distinct domains, a cytosolic V1 region and a membrane-bound
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Vo domain. Enzyme activity is fueled by the hydrolysis of ATP, which occurs at
the cytosolic V1 region of the complex. Proton translocation is then coupled to
ATP hydrolysis and occurs at a proton pore located in the integral Vo region [13]. The net acidification which results from a functional V-ATPase enzyme is
ultimately contingent upon the enzyme’s placement and orientation on a
membrane (organellar or plasma membrane).
Through its two-domain structure, the V-ATPase has adapted a unique
regulatory mechanism to respond to extracellular cues. In response to glucose
deprivation, the V1 and Vo sectors of the enzyme dissociate into separate, and
inactive, V1 and Vo domains [1, 2, 11]. Dissociation is a reversible and rapid
process, allowing the enzyme to quickly respond to a changing environment
because it does not require new protein synthesis [11]. In a given cell, there is
always a population of assembled and disassembled enzyme, the relative level of
each is constantly in a dynamic equilibrium. While the reveresible assemblydisassembly of the complex has not been shown to involve any conventional
signal transduction pathways that are activated by glucose deprivation, the
enzyme’s ability to respond to glucose levels has continued to be a strong point of
interest among researchers [12].
Through experimentation, the yeast V-ATPase has emerged as the
principal model system for studying eukaryotic V-ATPases because of its close
relation to higher eukaryotes and its receptiveness to genetic and biochemical
manipulation [1, 2]. In yeast, the V1 sector of the enzyme is comprised of eight
subunits labelled A, B, C, D, E, F, G, and H, and the Vo sector contains six
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identified subunits designated a, c, c’, c’’, d, and e [2, 13-15]. All yeast V-ATPase
subunits have homologs in higher eukaryotes which, in many cases, are similar
enough to allow them to functionally substitute one another in vivo [2, 13].
Perhaps the most endearing quality of yeast V-ATPase studies is the
presence of a conditional phenotype known as the Vma- phenotype. While loss of
V-ATPase function in higher eukaryotic organisms is often lethal, disruption of
any VMA (vacuolar membrane ATPase) gene in Saccharomyces cerevisiae
instead results in this characteristic phenotype [2, 15]. The Vma- phenotype is a
conditional lethality in which mutants lacking V-ATPase activity are capable of
growing on media buffered to pH 5 but unable to grow at elevated pH, elevated
extracellular calcium concentrations, on nonfermentable carbon sources, or in the
presence of various metals [2, 15]. The Vma- phenotype has proved invaluable in
genetic and biochemical studies helping to further characterize the enzyme’s
structure and function.
Much of what is known about V-ATPase structure and function has been
gleaned through comparison to the mitochondrial F-ATPase (ATP-synthase), an
enzyme with close evolutionary ancestry [1, 2, 16]. While the F-ATPase enzyme
essentially functions in reverse to the V-ATPase (ATP synthesis and passive
transport of protons vs. ATP hydrolysis and active transport respectively), the
enzymes still share significant homology in their catalytic mechanism and in the
core of their machinery [1, 2, 16]. Both V- and F-ATPases have a two-domain
structure, with a hexameric headgroup consisting of three catalytic and three
regulatory subunits alternating to comprise part of the enzyme’s extra-membrane
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fraction. V- and F-ATPases also share significant overlap in the structure and
layout of the proteolipids comprising their transmembrane proton pores. Given
these structural overlaps, it is not surprising that the enzymes also share a similar
catalytic mechanism, evoking the rotation of subunits spanning both cytosolic and
membrane-bound domains to coordinate energy expenditure with proton
movement [16-19].
While a common rotational catalytic mechanism stands as a foundation of
support for the evolutionary similarity between the V- and F-ATPase enzymes,
differences in how each enzyme provides for this mechanism showcase one of
many divergences in how the enzymes have evolved to suit their different cellular
roles [16-19]. Looking closely at the F-ATPase enzyme, structural studies have
identified two stalk structures which connect the cytosolic catalytic headgroup of
the F1 complex to the membrane bound Fo region of the enzyme [20]. These two
structures function as a “rotor”, whose movement between catalytic sites is fueled
by proton movement, and a “stator”, which tethers the cytosolic and membranebound domains together in a fixed position to allow for the rotation which drives
catalysis [20]. Together these central (rotor) and peripheral (stator) stalks serve to
create two well-defined connections between the enzyme’s sectors, allowing for
an efficient coupling of proton movement to ATP synthesis.
Unlike the F-ATPase, the interface between V1 and Vo is not as well
understood. While electron microscopy studies have shown both enzymes contain
clearly defined peripheral and central regions, the V-ATPase appears to have a
more complex structure with various protrusions emanating the V1 domain [21-

8

24]. Despite the fact that mechanistic studies have determined at least one rotor
and one stator are required to allow for the rotational catalytic mechanism, it is
possible that V1 may interact with Vo through multiple peripheral stalks [21, 22].
At least 4 V1 subunits (C, H, E, and G) are believed to form the peripheral
stalk(s) of the V-ATPase [2, 13]. Given the importance of the peripheral stalk(s)
in mediating a dynamic connection between V1 and Vo and in coupling proton
transport to ATP hydrolysis, each stalk subunit has unique properties which also
underlie aspects indigenous to the enzyme’s function and regulation. For instance:
subunits E and G have been shown to interact with the RAVE complex, a novel
complex involved in V-ATPase assembly, but the role of this interaction is not
well understood [13, 25]. Subunit C has also been shown to interact with the
assembly complex RAVE [Smardon unpublished], and is also able to separate
from free V1 in the cytosol when the V-ATPase dissociates in vivo [2, 13,
Smardon unpublished data]. Interestingly, subunit H has been the only subunit
identified which is required for activity but not assembly of the enzyme [26, 27].
The H subunit has been implicated in the suppression of V-ATPase activity in
free V1 domains upon enzyme disassembly [28] and the two domains of the
subunit (N- and C-terminal) have recently been shown to make complementary
contributions to structural and functional coupling of the peripheral V1 and
membrane Vo sectors of the V-ATPase [29]. The N-terminal domain alone is
sufficient for activation of ATP hydrolysis in V1, but the C-terminal domain is
essential for proper communication between the V1 and Vo sectors. Interestingly,
the coupling of V1 to Vo does not require that they be joined covalently [29].
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While the precise arrangement of all peripheral stalk subunits still remains
uncertain, their interacting partners, in addition to an expanded list of identified
roles for the proteins, have highlighted the potential of these proteins as a key
targets for intracellular regulators.
Given the frequently tight stoichiometry of multi-subunit complexes, it is
not surprising that both the V- and F-ATPase have documented cases of dosage
sensitivity. In the V-ATPase, overexpression of stalk subunits C and H has been
shown to destabilize the enzyme, uncoupling proton transport from ATP
hydrolysis [30], and overexpression of subunit G (Vma10p) has been shown to
destabilize E subunit levels (Vma4p) [31]. Differing from the V-ATPase, genetic
data from F-ATPase studies has indicated that reducing the gene copy number for
certain rotor subunits (γ and δ) allows for the formation of subunit-deficient
complexes in diploid cells [32, 33]. Subunit-deficient complexes and phenotypes
resulting from gene copy reduction were biochemically significant because they
caused partial uncoupling at the mitochondrial membrane and stand as a clear
case of haploinsufficiency for the enzyme [33].
In haploinsufficient diploid F-ATPase mutants, the phenotypes (slow
growth and loss of mitochondrial DNA) were alleviated by adding an epistatic
null mutation to remove all ATPase activity in the enzyme and its complexes.
This epistatic interaction supports a hypothesis that the subunit-deficient
complexes formed had a gain in activity when gene copy was reduced from 2 to 1
for α or β genes.
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The findings of haploinsufficiency for key F-ATPase rotor proteins
suggested the previously unexplored possibility of haploinsufficiency among the
VMA genes. In this study, we explored the possibility of haploinsufficiency
among all VMA genes, helping us to identify a clear haploinsufficiency for the
VMA13 gene (encoding subunit H). The importance of VMA13 gene product as
both a peripheral stalk protein and structural/functional regulator of the enzyme
led us to investigate the biochemical basis of this haploinsufficiency. Selectively
forming compound heterozygous mutants by crossing vma13D strains to various
VMA knockouts (see Figure 3), our analysis provided additional evidence of
compound haploinsufficiencies involving the H subunit.
Together, subunit location and phenotypes of compound heterozygous
mutants has led us to determine that a perturbation of H subunit stoichioimetry
creates a gain in ATPase activity in the stable population of free V1 sectors in the
cytoplasm and that this population’s levels and activity underlie many subsequent
phenotypes for single and compound heterozygous mutants of VMA13.
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Materials and Methods
Materials and Media—Concanamycin A was purchased from Wako
Biochemicals, and Zymolyase-100T was purchased from MP Biomedicals, Inc.
G418 drug, Tween-20, N-ethyl maleimide, FLAG peptide, and all protease
inhibitors (Leupeptin, Aprotinin, Pepstatin, and Phenylmethanesulfonyl fluoride
(PMSF)) were obtained from Sigma. ClonNat drug was purchased from Werner
Bioagents. 5FOA (5-fluoroorotic acid) was purchased from Lab Scientific. Yeast
medium was prepared as described by Sherman et al [34].
Strains and Plasmids—Wild-type yeast strains BY4741/ BY4742 and vmaΔ
mutants used were part of a yeast deletion mutant array purchased from Research
Genetics. The BY4741 vma13 ::kanMX strain contains a precise deletion of the
VMA13 open reading frame with the kanMX marker flanked by a set of marker
sequences [35]. Construction and characterization of the wild-type VMA13
plasmid containing an N-terminal Myc tag was described previously [36]. This
plasmid was used previously as the template for construction of the VMA13-NT
and VMA13-CT mutant plasmids [29].
All plasmids were introduced into heterozygous deletion strains using an
overnight lithium acetate transformation protocol [37], and transformants were
selected on supplemented minimal medium lacking uracil (SD-uracil) for
pRS316-based plasmids or lacking leucine (SD-leucine) for pRS315-based
plasmids.

12

Single heterozygous diploid cells were selected by mating library vma
deletions (BY4741 vma ::kanMX strains) to library BY4742 (opposite mating
type) and selecting zygotes under a Zeiss dissection microscope (Figure 3A).
Compound heterozygous diploid cells were selected by mating a BY4742
vma13 ::natr strain to library vma deletion strains (BY4741 vma ::kanMX
strains) and selecting for antibiotic resistance to both clonNat and G418 (Figure
3B). The BY4742vma13Δ::natr strain was created by switching the kanMX
marker in the BY4742vma13Δ::kanMX mutant to natr as described by Tong et al
[48]. Single heterozygous vma13 mutants were also selected by mating a
BY4742 vma13Δ::natr strain. The need for double selection of G418/Nat media
arose because of the instability of the diploids selected. Since many of the
compound heterozygous mutants we worked with had severe growth/biochemical
defects, cell populations were constantly adapting mechanisms to compensate for
their defects as they divided. This microevolutionary compensation was seen in
the lessening of phenotypes over time as cell strains were continually streaked,
selecting against defective populations (those that grow poorly or not at all) and
for compensatory mutants (those that alleviated defects and grew better). We
suspect that compensation was either though chromosomal duplication,
homologous recombination, integration of plasmid gene copy, or possibly through
other mechanisms. A visual manifestation of such these spontaneously reverted
mutants can be found in Figure 13, where one deficient cell lines such as vma13Δ
x vma3Δ strains show some colony growth upon plasmid loss. These small
colonies would represent the compensated subpopulation of mutant strains which
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we hoped to select against through our methodology. In order to avoid
complementation mechanisms and these reverted subpopulations in unstable
diploids, we used the BY4741ydr029wΔ strain as a marked wild-type strain to
allow for double selection of our compound heterozygous mutants. The
BY4741ydr029wΔ::KanMX strain is a dubious ORF deletion located nowhere
near any VMA or VMA-impacting pathways. It has yet to show any involvement
in Saccharomyces cerevisiae. For these reasons the BY4741ydr029wΔ::KanMX
strain was used as a pseudo-wild-type in all of our experiments to allow us to
maintain conditions of double selection. Therefore, in our Results sections,
vma13Δ x wt is really the vma13Δ x yrd029wΔ strain.
To further avoid complementation mechanisms (such as chromosome
duplication and/or homologous recombination) we also carried all heterozygous
vma13Δ strains with a plasmid-borne VMA13 containing an N-terminal Myc tag.
Supplying this additional copy of VMA13 kept normally dosage-insufficient cells
at wild-type health up until the time of experimental characterization upon which
we would subject the cells to media including 5FOA. Since 5FOA is lethal in the
presence of the VMA13 plasmid URA3 marker, this media did not allow
complemented heterozygous diploid strains to maintain plasmid and selected for
plasmid loss. Therefore, the use of both double selection media
(ydr029wΔ::kanMX in place of wild-type) and plasmid complementation prior to
experimental characterization helped us avoid previous problems with
heterozygous diploid instabilities, including variable growth phenotypes, variable
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acidification in vivo and high standard errors amongst V-ATPase specific
activities.
Our wild-type diploid strain was borrowed from Dr. Scott Erdman of
Syracuse University’s Department of Biology and was initially purchased as part
of a deletion library from Research Genetics.
Biochemical Methods—Vacuoles were obtained as described previously by
Raymond et al, except that strains containing plasmids were grown in
supplemented minimal medium to maintain the plasmid prior to lysis, and the
cells were grown to an A600 of 1.0 before harvesting [40]. Yeast whole cell
lysates and vacuolar vesicles were prepared for SDS-polyacrylamide gel
electrophoresis and immunoblotting as described previously using using mouse
monoclonal antibodies 8B1, 13D11, and 10D7, monoclonal antibodies against the
A, B, and a subunits, respectively, of the V-ATPase or monoclonal antibody 1D3
against yeast alkaline phosphatase [38]. Protein concentrations were determined
by Lowry assay [46]. ATP hydrolysis rates were assessed using a coupled
enzyme assay at 37 °C as described by Lotscher et al [45]. Proton pumping was
measured on a SPEX Fluorolog-3-21 fluorometer by the ACMA quenching assay
as described by Shao and Forgac [39]. Vacuolar vesicles were assayed exactly as
described previously [29, 38].
Purification of Cytosolic V1 Complexes— FLAG tagged vma mutant strains were
constructed to allow for selection of cytosolic V-ATPase complexes in each
mutant analyzed. For vma13Δ x wt strains a vma13Δ x vma10Δ/VMA10-FLAG
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strain was constructed. For vma13Δ x vma2Δ cells a vma13Δ vma10Δ/VMA10FLAG x vma2Δ strain was constructed. For vma13Δ x vma3Δ cells a
vma13Δvma10Δ/VMA10-FLAG x vma3Δ strain was constructed and for vma3Δ
x wt a vma3Δ x vma10Δ/VMA10-FLAG strain was constructed.
All strains were constructed using antibiotic diploid selection and/or dissection
microscopy as described previously. With only one copy of FLAG-tagged
VMA10, each constructed strain allowed only a sampling of free V1 populations
present in vivo, with the total population of free V1 complexes in mutant strains
unknown using this metholodology alone.
FLAG-tagged cells were grown overnight to mid-log phase (1-3 A600/ml) in SD –
Leu media to select for plasmid. All log-phase cells (2000- 6000 A600 units of
cells) were harvested by centrifugation at 4000 x g for 10 min and resuspended in
100 ml of 50 mM Tris HCl pH 7.5, 1.2M sorbitol, 2% glucose, 1% βMercaptoethanol solution.
Cells were converted to spheroplasts by adding zymolyase 100T (50 units/gram of
cells) to the cell suspension and gently shaking at 30 °C for 20 min. Spheroplasts
were then washed twice with 300 ml of YEPD medium containing 1.2 M sorbitol.
Spheroplasts were not deprived of glucose to avoid influencing the amount of free
V1 complexes isolated.
After washes, spheroplasts were collected by centrifugation at 4000 x g for
10 min. Cells were resuspended in 50 mL of phosphate buffered saline plus .05%
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Tween-20 (TBSE) with protease inhibitors (1 µg/ml Leupeptin, 5µg/ml Aprotinin,
1µg/ml Pepstatin, 1mM PMSF) and disrupted using a microfluidizer processor
from Microfluidics. Disrupted lysates were then spun at 4000 x g for 20 min and
the resulting supernatant was subjected to ultracentrifugation at 52.1K for 2 hours.
Supernatant from the ultracentrifugation was syringe filtered and concentrated to
approximately 10 mL using a Centricon Plus-20 centrifugal filter device kit by
Millipore. 10 mL samples were then loaded twice onto an anti-FLAG column
composed of FLAG antibody attached to beads purchased from Sigma [47].
FLAG-tagged V-ATPase was subsequently eluted with 2.5 ml of 100 µg/ml
FLAG peptide in TBSE. The V-ATPase was eluted as five 500µl fractions after
which the column was washed with 2.5ml of TBSE, also collected in five 500µl
fractions.
ATPase activity of isolated fractions was analyzed as described previously
[45], however, N-ethyl maleimide (NEM) was used as a specific inhibitor of the
V-ATPase in place of concanamycin A. Inhibition by 50µM N-ethyl maleimide
(NEM) of free V1 ATPase activities was determined by mixing 10 µg of protein
from column fractions with 50 µM N-ethyl maleimide and incubating for 20 min
on ice. This mixture was then added to the ATPase assay mixture and hydrolysis
rates were determined the same as described above. Fractions were also analyzed
for the presence of V1 subunits by Western blotting, and Coomassie Blue staining
as described previously [36, 38]. V1 subunits were immunoprecipitated under
nondenaturing conditions [36].
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Quinacrine Staining of Whole Cells—Quinacrine labeling was performed as
described [40], and labeled cells were observed within 10 min of labeling.
Quinacrine fluorescence was observed using a Zeiss Axioskop II fluorescence
microscope equipped with a Hamamatsu ORCA CCD camera.
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Results

Haploinsufficiency of VMA genes
To explore the possibility of haploinsufficiency of VMA (vacuolar
membrane ATPase) genes, we began our analysis by mating various vma deletion
mutants to wild-type cells in order to construct heterozygous diploid mutants
reduced in copy for a given VMA gene (Figure 3A). This initial diploid selection
was conducted using a dissecting microscope to identify zygotes and the
heterozygous diploids selected were subjected to a variety of conditions to assay
growth phenotypes.
Through the use of serial dilutions, where equal quantities of cells are
grown and compared, quantitatively, the growth of heterozygous vma diploid
mutants was assayed on conditions of pH 5, 7.5, and 7.5 + extracellular calcium.
Of the many combinations selected, a reduction in gene copy from 2 to 1 for the
VMA13 gene showed the strongest and most consistent phenotype among all
heterozygous vma mutants. As shown in Figure 4, all heterozygous vma13Δ
mutants showed a Vma- like phenotype, indicative of acidification defects, with
poor growth on elevated pH and in the presence of extracellular calcium. In
addition to a Vma- like phenotype, diploid cells lacking one copy of the VMA13
gene also, at times, exhibited extremely slow growth on pH 5 media. Since pH 5
is normally a condition that is sufficient for mutants with V-ATPase defects to
survive and flourish, this result also suggested defects with the enzyme.
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In addition to heterozygous vma13Δ mutants, other heterozygous vma
mutants also, at times, showed reduced growth compared to wild-type cells such
as heterozygous vma3Δ or vma10Δ mutants (Figures 4-7), however the slow
growth phenotypes in addition to the strong Vma-like qualities of heterozygous
vma13 mutants consistently caught our interest.
The unique phenotypes of heterozygous vma13Δ mutants compared to
other heterozygous mutants for both V1 and Vo subunits (Figure 4) was an
intriguing result because of the H subunit’s role as a structural and functional
coupler of the enzyme’s two-domains [29]. Given the defects in vacuolar
acidification which typically underlie a Vma- phenotype, we proceeded to
examine the in vivo vacuolar acidification of a vma13Δ x wt strain by looking at
the quinacrine staining of vacuoles. Quinacrine is a fluorescent lysosomotropic
amine which accumulates in acidic cellular compartments such as the vacuole.
As expected, vacuoles from mutants heterozygous for vma13Δ showed
reduced uptake of quinacrine compared to wild-type, indicating a defect in in vivo
acidification (Figure 8A). Complementation with a vma13 N-Myc plasmid
returned staining to near wild-type levels, confirming that this loss in acidification
was indeed due to a reduction of VMA13 gene copy (Figure 8B). Because of
recent evidence suggesting separate roles for the VMA13 protein’s N and Cterminal domains [29], an independent complementation experiment was also
conducted to see if either domain could rescue vacuolar acidification. Strains
given either VMA13-CT or –NT alone gave similar results with increased
quinacrine uptake relative to a heterozygous vma13Δ x wt strain but less uptake
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compared to that of a full-length VMA13 complementation (data not shown). This
result suggests that a reduction in either C- or N-terminal domains of VMA13 is
capable of having a physiological effect on the cell and that the relative levels of
both domains can influence the enzyme’s activity. The apparently equal dosage
sensitivity of both C and N-terminal domains of VMA13 can most likely be
attributed to the tight stoichiometric ratio of H subunit required in a functional
enzyme complex [29, 30].

Compound Haploinsufficiency among VMA genes

Because multi-subunit protein complexes are most often affected by
haploinsufficiency [33, 41], we decided to further investigate the growth and
acidification phenotypes exhibited by vma13Δ x wt cells by constructing an
additional set of compound heterozygous deletion mutants. Compound
heterozygous diploid mutants were constructed by mating two vma deletion
strains (of opposite mating type) and selecting for diploids by antibiotic resistance
(Figure 3B).
In analyzing compound mutant phenotypes, our initial intention was to
search for possible epistatic interactions that could alleviate the phenotypes
discovered for heterozygous vma13Δ mutants. A search for epistatic mutations
was prompted by from previous haploinsufficiency studies on the related
mitochondrial F-ATPase, in which the activity of partial complexes of the
enzyme, formed upon specific subunit reductions, was eradicated by a second
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epistatic heterozygous mutation [33]. Equally inspiring for our search was the
potential for uncovering new compound phenotypes not found in single
heterozygous mutants, because a second heterozygous mutation could, very
likely, push a vulnerable cell past its breaking point, especially when dealing with
potentially limiting proteins in a multi-subunit complex [30, 33, 41].
Based on our initial analysis of all heterozygous vma mutants (complete
analysis not shown, see Figure 4) we decided to look at various combinations
involving key subunits such as subunits c, G, and H (VMA3, VMA10, and
VMA13 respectively). The possibility of compound heterozygous mutant
phenotypes was investigated with these three subunits because they showed some
sensitivity as single heterozygous mutants (Figure 4-7). Also, since previous
studies had already demonstrated the sensitivity of subunits G and H to gene
dosage levels, these were obvious choices [30, 31].
Through our experiments we learned that reducing the gene copy for
subunits in addition to VMA13 was beneficial not only in discovering epistatic
interactions however, but also in uncovering the biochemical basis of phenotypes
surrounding the level of expression of VMA13. By genetically manipulating the
levels of more than one subunit in a diploid cell, we were able to identify several
modified phenotypes. These modified phenotypes were a direct result of
disrupting the stoichiometry of other key subunits within the complex in tandem
with our vma13Δ heterozygous deletion.
Figures 5, 6, & 7 show the growth phenotypes for various compound
heterozygous vma mutants constructed. Given previous phenotypes for single
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heterozygous mutants (Figure 4) it was not surprising that most of the Vma-like
phenotypes exhibited during this experiment involved a reduction of VMA13
gene dosage. Focusing in on the possible combinations of vma13Δ compound
heterozygous mutants, our results showed a consistently exacerbated phenotype
for heterozygous vma13Δ diploids combined with a heterozygous
vma3Δ mutation. In all scenarios (Figures 5 & 7), addition of a vma3
heterozygous deletion to a heterozygous vma13Δ diploid resulted in a more
severe growth phenotype, not only affecting growth on elevated pH and calcium
concentrations but also significantly reducing growth on pH 5 (Figures 5 & 7).
Considering the fact that a single vma13Δ heterozygous mutant only slowed
growth on pH 5, the much greater growth reduction of a compound
vma3Δ heterozygous mutation suggested more serious problems with the VATPase enzyme. In addition to these severe phenotypes, the reduction of VMA3
gene copy in tandem with that of VMA13 also resulted in severe acidification
defects in vivo, showing virtually no quinacrine uptake when assayed (Figure 8C).
Besides the effects of vma3Δ heterozygosity on heterozygous
vma13Δ mutants, other mutations in key V1 subunits such as the regulatory B
subunit (Vma2p) led to interesting phenotypes as well. Deletions in various V1
subunits essential for ATPase activity of the enzyme led to an epistatic interaction
when combined with a heterozygous vma13Δ mutation. For example, strains
reduced in gene copy for both VMA13 and VMA2 showed better growth on
elevated pH and in the presence of extracellular calcium (Figure 7). In addition to
this improvement in growth, a vma13Δ x vma2Δ strain also exhibited partial in
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vivo acidification, showing a noticeable increase in quinacrine uptake compared
to a single heterozygous vma13Δ mutant, but still less than that of wild-type cells
(Figure 8D).
While, vma13Δ x vma2Δ and vma13Δ x vma3Δ compound heterozygous
mutants displayed identifiable phenotypes, other combinations offered less
obvious effects on the cell and V-ATPase activity. In some cases certain
combinations of heterozygous vma deletion mutants produced subtle growth
phenotypes. For instance, as shown in Figure 5, combinations of vma3Δ x
vma10Δ and vma3Δ x vma5Δ heterozygous mutations produced a subtle growth
defect, but only at pH 7.5 with extracellular calcium added. Similar phenotypes
were seen for vma10Δ x vma13Δ heterozygous mutants (Figures 6 & 7) and
vma10Δ x vma8Δ heterozygous mutants, which showed poorer growth at pH 7.5
in addition to these phenotypes (Figure 6). It should be noted that all heterozygous
mutant combinations were assayed at both 30C and 37C; however, few
temperature-dependent differences in growth existed (data not shown). Despite
the fact that several combinations of heterozygous vma mutations produced subtle
growth defects, both the strength and consistency of our data with VMA13 fueled
the obvious decision to further investigate these compounded phenotypes
biochemically.

Biochemical Phenotypes of Dosage Sensitive Mutant Vacuoles
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As shown in Figures 4-7, a consistency throughout many of our assays
involving VMA13 subunit reductions existed: a vma13Δ x vma3Δ heterozygous
mutation combination exacerbated phenotypes while compound mutations in V1
subunits necessary for ATPase activity appeared to improve haploinsufficiency
phenotypes. This improvement was seen at all conditions assayed and illustrated
an epistatic effect of these additional vma mutations (Figure 7).
While most combinations of heterozygous vma mutations appeared to
improve the growth of compound vma13Δ heterozygotes, we chose to further
investigate the vma13Δ x vma2Δ heterozygous strain, and its epistatic phenotypes
biochemically, because of the B subunit’s (Vma2p) role as a regulator of the
enzyme (required for ATPase activity), in addition to its multi-copy presence in
the enzyme complex [1, 2].
To examine the biochemical properties of V-ATPases containing the
various combinations of heterozygous vma deletions we isolated vacuolar vesicles
from both single and compound heterozygous vma13Δ mutants. Table One shows
the total ATPase specific activities calculated for each of the vacuolar vesicle
preparations. We generally assess V-ATPase specific activity by measuring the
proportion of total ATPase activity that is sensitive to 100nM concanamycin A.
Concanamycin A is a specific inhibitor of the V-ATPase and acts by targeting the
proton pore of the enzyme’s Vo domain.
As shown in Table One, the specific activity of a typical vma13Δ x wt
mutant is reduced to roughly half that of wild-type levels (.58 compared to 1.17).
When combined with a compound heterozygous vma3Δ mutation however,
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vma13Δ x vma3Δ strains show an even more severe defect in ATPase activity,
with a near-zero specific ATPase activity (.03). The reduced specific activities for
vma13Δ x vma3Δ or vma13Δ x wt strains were also seen in vacuoles of a
vma13Δ x vma2Δ background. In contrast to the improvement in growth and
quinacrine uptake, combining a heterozygous vma13Δ mutant with an additional
heterozygous vma2Δ mutation did not increase ATPase specific activity at the
vacuole relative to the vma13Δ x wt strain. The specific activities of vma13Δ x
vma2Δ vessicles were also near half those of wild-type vesicles (.54) with very
similar activity levels compared to single heterozygous vma13Δ strains (Table
One).
In addition to heterozygous and compound heterozygous vma deletion
strains including a reduction in VMA13 copy, our analysis also provided several
controls to help focus on what defects in ATPase activity were VMA13-specific.
Besides using a wild-type diploid as a control, we also measured the ATPase
activity for a vma3Δ x wt strain to see what effects a heterozygous mutation for
vma3 could cause alone. Since the specific activity of a heterozygous vma3Δ
strain was practically the same as wild-type levels (1.09 compared to 1.17), it is
clear that a compound vma13Δ x vma3Δ has synergistic negative effect on
ATPase activity at the vacuole (Table One). The wild-type-like ATPase activity,
in vivo acidification (Figure 8E), and growth of a heterozygous vma3Δ strain
allowed it to serve as a strong control for the inherent effects of reducing a nonlimiting/non-sensitive subunit, to contrast our analysis of reducing subunits
present in tight stoichiometric ratios.
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In addition to our wild-type diploid and heterozygous vma3Δ strain, a
third control was used in attempt to identify VMA13-specific haploinsufficient
biochemical phenotypes. By complementing a vma13Δ x wt strain with a lowcopy VMA13-Nmyc plasmid, we attempted to return VMA13 gene copy to wildtype levels. As evidenced by the inability of our vma13Δ/VMA x wt strain to
rescue ATPase activity at the vacuole however (Specific Activity of .67 for a
complemented strain to .58 ), complementation of a heterozygous vma13Δ strain
was incomplete.
The lack of complementation in a vma13Δ/VMA13 x wt strain was also
manifested in other assays (see next section) and is most likely attributed to the
fact that a N-terminal Myc plasmid provides an unknown dosage of VMA13.
While a Myc plasmid is not a high-copy vector, it is almost inevitable that this
extra-chromosomal DNA does not provide the exact gene dosage needed to attain
the extremely tight stoichiometry of the Vma13p [29, 30]. For this reason our
results were not unexpected and we shifted our focus to both wild-type diploid
and vma3Δ x wt strains as positive controls. It should be noted however that some
positive effects of a VMA13-Nmyc plasmid complementation to our vma13Δ x
wt strain were seen in biochemical analysis such as Quinacrine Uptake (Figure 8).
In general however, the poor growth of heterozygous vma13Δ cells (single and
compounded) made it difficult for them to maintain the plasmid, most likely
because the dosage of VMA13 gene copy it provided was not at a wild-type level.
Plasmid complementation also failed to rescue a variety of biochemical defects,
all of which were analyzed after organelle isolation, suggesting that the unstable
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vacuoles of these strains could not maintain any complemented activity, if they
had any in vivo, because of improper gene dosage.
In addition comparing ATPase activity for mutant vacuoles, vacuolar
proteins were subjected to SDS-polyacrylamide gel electrophoresis and
immunoblotting by transferring separated proteins to a nitrocellulose membrane
and probing for V-ATPase subunits with specific monoclonal antibodies. By
probing for the presence of the regulatory B subunit (Vma2p), the catalytic A
subunit (Vma1p), and the peripheral stalk C subunit (Vma5p), we were able
ascertain a rough quantification of how much V1 was present the vacuolar
membrane of each strain. Probing for the Vo a subunit (Vph1p) also gave us an
indication of Vo subunit levels in the vacuole.
Comparing the relative levels of subunits A, B, C, and a (Vma1p, Vma2p,
Vma5p, and Vph1p respectively) allowed us to get an idea of overall V-ATPase
assembly and stability at the vacuolar membrane. Often times vacuolar vesicles
showing high Vo subunit levels and relatively low V1 subunit presence suggest an
increased population of disassembled enzyme. Additionally, the instability of
improper subunit expression often manifests itself in destabilized the protein
levels for other subunits, as was the case for VMA10 overexpression (G subunit)
destabilizing E subunit levels (Vma4p) [31].
We began our analysis of V-ATPase protein levels for each mutant strains
by probing for the alkaline phosphatase protein (Figure 9A). Since alkaline
phosphatase is a known vacuolar protein that exists independent of the V-ATPase,
this control allowed us to confirm that the proteins we analyzed were part of intact
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V-ATPases present at the vacuole membrane. Since this protein was present in all
strains at roughly equal levels, the assay also allowed us to confirm that roughly
equal amounts of proteins were loaded on each blot, giving us the ability to
quantify our data (Figure 9).
Examining the equal, and quantifiable, levels of vacuolar proteins using
specific monoclonal antibodies for V-ATPase subunits, it was apparent that in a
vma13Δ x vma3Δ compound heterozygous mutant, enzyme assembly at the
vacuole was decreased relative to wild type, with reductions in all of the subunits
probed a, C, A, & B (Vph1p, Vma5p, Vma1p, & Vma2p respectively) compared
to wild type levels. This reduction in subunit expressions for
vma13Δ x vma3Δ heterozygous strains was far more severe compared to the
single vma13Δ heterozygous strain, which also showed less V-ATPase assembly
(lower levels for subunits A and B) but without the same reductions of subunit a
and C levels. Interesting of the vma13Δ x wt strain was the near absence of A
subunit at the vacuole (Vma1p). The lack of this catalytic subunit, indicated a
reduction beyond that seen for the regulatory B subunit (Vma2p) and was
confusing because both proteins are from the same region (V1) and present at the
same dose (3 copies each) in the enzyme complex (Figure 9).
Since, in all cases studied, a vma13Δ x vma3Δ compound heterozygous
mutant showed a worse growth phenotype relative to a single vma13Δ compound
heterozygous mutant, a severe decrease in V-ATPase subunit levels was not
unexpected. Despite our anticipations however, an unexpected result was found in
the absence of both catalytic (A) and regulatory (B) subunits at the vacuolar

29

membrane for vma13Δ x vma3Δ heterozygous strains. While a reduction in Vo
subunit expression, such as that of Vma3p (c), could destabilize the levels of other
subunits (as was the case for the vma3Δ x wt strain), a vma3Δ heterozygote
should still have one intact copy of wild-type VMA3. The complete absence of
V1 subunit copies (Vma1p, Vma2p, and Vma5p) is puzzling because some
amount, however small, of wild-type Vo subunits, specifically VMA3 subunits,
should exist and allow for V1 attachment.
Our results of having no V1 at all at the vacuolar membrane for
vma13Δ x vma3Δ strains, suggest that the enzyme doesn’t assemble at all, despite
having one wild-type copy of VMA3. This finding implies that reasons in
addition reduced Vo sites for attachment are responsible for a vma13Δ x vma3Δ
strain’s assembly differences from a single heterozygous vma13Δ mutant. The
low levels for all subunits probed (both V1 and Vo) certainly lends itself to the
possibility that defects in overall enzyme biosynthesis and/or instability may be
contributing factors responsible for this difference. Regardless of the explanation
however, the differences (unexpected or not) for a vma13Δ x vma3Δ strain’s
subunit expression levels testifies to the synergistic effects of a compound
vma13Δ x vma3Δ heterozygous mutant.
Contrasting the subunit levels for vma13Δ x wt and vma13Δ x vma3Δ
strains, our western analysis of both V1 and Vo subunit levels in a vma3Δ x wt
strain gave an indication of what subunit reductions could be expected when
altering the level of a non-limiting subunit. As seen by the reduced levels of
Vph1p (a subunit) relative to wild-type, a heterozygous mutation in vma3 can
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lower subunit levels however, a functional, stable, and assembled population of
V-ATPase is remains evident. Such populations were also seen in the vma13Δ x
vma2Δ strains whose levels of V1 subunits A and B (Vma1p and Vma2p) were
the same as those of wild-type diploid cells while Vo subunit a (Vma3p) was
reduced to a level near the heterozygous vma3Δ strain.
It should also be noted that the near equivalent amounts of V1 subunits
for vma3Δ x wt, despite the reduced presence of Vma3p, compared to wt diploid
suggests that much of the Vo seen at the vacuole of a wild-type diploid cell is not
bound to V1. This further supports our use of heterozygous vma3Δ cell line, and
its protein levels, as a control for looking at protein levels in assembled V-ATPase
at vacuolar membranes.
In addition to our findings, in this particular experiment, complementation
of a heterozygous vma13Δ mutation with the VMA13-Nmyc plasmid was
successful in terms of increasing some V1 subunit levels (Vma1p & Vma2p) to
wild-type levels and Vo subunit levels (Vma3p) to the levels comparable to the
vma3Δ x wt strain. While the presence of these subunits at increased levels
confirms their expression it is possible that the dose of VMA13 provided is still
perturbed enough to hinder or inhibit proper assembly of the enzyme complex,
even amid ample levels of non-VMA13 subunits. Similar results were seen with
VMA13 overexpression [30].
In addition to examining protein levels of V-ATPase subunits, we also
assayed the proton-pumping abilities of both wild-type and mutant V-ATPases by
ACMA fluorescence quenching. ACMA (9-amino-6 chloro-2-methoxyacridine) is
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a fluorescent dye that binds to membranes and exhibits changes in its fluorescent
properties as a pH gradient forms. Quenching of ACMA fluorescence can be
monitored as a
means of measuring proton pumping across a membrane. As shown in Figure
10A, both vma13Δ x wt and vma13Δ x vma3Δ strains showed no pumping when
assayed. Given the documented lack of ATPase activity for and vma13Δ x vma3Δ
strains (Table One) this result was expected however, the lack of pumping in
single heterozygous vma13Δ strains suggests that VMA13 dosage reduction can
cause an uncoupling of ATPase activity and proton translocation at the vacuole
(Figure 10A). Uncoupling of the V-ATPase enzyme is reflected by the enzyme
having ATPase activity but not establishing acidification, either by failing to
pump protons or having a proton leak at the membrane. Such processes stand as a
waste of intracellular energy stores and could have profound implications for cell
growth.
It is interesting to note that the inactive and non-pumping enzyme found
at the vacuolar membrane for vma13Δ x vma3Δ strains cannot be responsible for
the exacerbated phenotypes compared to a vma13Δ x wt strain, because a
vma13Δ x wt strains has an uncoupled enzyme and should be actively depleting
cellular ATP stores, unlike the inactive vma13Δ x vma3Δ strain. Given the
difference in growth between vma13Δ x vma3Δ and vma13Δ x wt strains we were
again forced to look beyond the vacuolar membrane for a biochemical basis of
phenotypic differences (see next section).
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Different from the negative effects on pumping for both vma13Δ x wt and
vma13Δ x vma3Δ strains, a vma13Δ x vma2Δ showed an ability to pump protons
to about half the level of wild type pumping (Figure 10B). Since vma13Δ x
vma2Δ cells have about half the ATPase activity of wild-type (Table One), this
ability to pump showed that V-ATPase that does assemble in a vma13Δ x
vma2Δ strain is far better coupled, compared to the uncoupled vma13Δ x wt
strain. This improvement in coupling is most likely one, of possibly several,
factors contributing to the strain’s improved growth, offering insight into some of
the phenotypes of vma13Δ x vma2Δ mutants compared to vma13Δ x wt strains.
Comparing the biochemical phenotypes of all vma13Δ heterozygous
diploid combinations helped us to see just how influential a subunit reduction for
VMA13 can be. Since the specific activity of a heterozygous deletion for vma3Δ
alone had no pronounced effects compared to wild-type for total specific ATPase
activity (Table One), overall growth (data not shown), in vivo acidification
(Figure 8), or proton pumping (Figure 10C) it is safe to say that the combination
of reducing both VMA13 gene dosage and VMA3 gene dosage is responsible for
the extreme phenotypes of vma13Δ x vma3Δ mutants, rather than a
vma3Δ heterozygous mutations causing its own independent problems. Together,
these results support the destabilizing effects of reducing VMA13 dosage,
especially when in tandem with a VMA3 reduction.
It is also of interest that the ATPase activity of all vacuolar vesicles
containing a heterozygous vma13Δ mutation was notably less stable than that of
wild-type vesicles. While wild-type vesicles typically retain most ATPase activity
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and proton pumping after extended freezing or when incubated overnight on ice,
such stability was not seen for the vma13Δ x vma2Δ or vma13Δ x wt vesicles
which initially showed activity upon isolation. When left overnight or frozen and
re-used, vma13Δ x vma2Δ or vma13Δ x wt vesicles showed a considerable loss in
activity and/or pumping, if they retained any at all. This tendency of vma13Δ
mutants to show unstable ATPase activity has also been seen in recent studies on
the H subunit [29]. The instability of heterozygous vma13 mutants was in contrast
to the stability of heterozygous vma3Δ vacuole activities and pumping after
freezing or incubation on ice (data not shown).

Biochemical Phenotypes of Dosage Sensitivity in Cytosolic V1 Complexes

Previous studies on the mitochondrial F-ATPase showed the potential for
active F1 complexes to form in the mitochondria when certain subunits were
present at reduced copy [33]. In addition, active V1-ATPase complexes have been
detected in the cytosol under certain conditions [28]. Therefore, we expanded our
biochemical analysis of single and compound heterozygous vma mutants to
account for potential cytosolic V-ATPase activity.
We looked at the activity of each strain’s free V1 population by using a
FLAG affinity column [47] as described in the Methods section. Using this
column, we were able to isolate a sampling of the free V1 population found in
each strain tested and then were able to compare the specific ATPase activity in
this cytosolic V1 population (See Methods).
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Given the previous experiments by Parra et al [28], which identified the
role of the Vma13p in inactivating free V1 sectors of the enzyme, we anticipated
the cytosolic V-ATPase fraction of our vma13Δ heterozygous mutants might
show some increased ATPase activity relative to wild-type levels, which it did
(Table Two). Like Parra et al [28], we attribute this activity to free V1 complexes
lacking subunit H. Of more interest in our analysis, however, was the comparison
to cytosolic ATPase activity of compound VMA13 heterozygous mutants
(vma13Δ x vma3Δ and vma13Δ x vma2Δ) whose growth and biochemical
phenotypes differed from a single heterozygous vma13Δ strain.
Comparing the Specific Activity for peak free V1 fractions isolated, a
compound vma13Δ x vma3Δ mutant showed a significant increase in Specific
Activity, with a value twice that compared to a single heterozygous vma13Δ
strain (Table 2). This difference in Specific Activity between the heterozygous
vma13Δ x vma3Δ mutant and its single heterozygous vma13Δ counterpart must
be accounting for the exacerbated phenotypes of a vma13Δ x vma3Δ mutant,
given the presumably worse situation at the vacuole for the uncoupled
heterozygous vma13Δ strain.
In addition to differences in Specific Activity for vma13Δ x vma3Δ and
vma13Δ x wt strains, the cytosolic V1 fractions of heterozygous vma13Δ x
vma2Δ mutants also showed a noticeable change in activity. Mutants
heterozygous for both vma13Δ and vma2Δ showed a decrease in Specific
Activity, perhaps due to a better stoichiometry between subunit H (Vma13p) and
the B subunit (Vma2p), which is essential for V1 assembly (suggesting that this
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reduction in activity is, at least, partially responsible for improved growth
phenotypes) (Table 2).
Equal amounts of all fractions with ATPase activity were separated via gel
electrophoresis and stained with Coomassie Blue Dye (Figure 11A) as well as
examined via Western analysis probing for V1 subunits A and B (Figure 11B).
Together, Coomassie and Western analysis clearly confirm that our Specific
Activity values calculated were for similar protein profiles, all of which included
relatively equal amounts of free V1 from the V-ATPase enzyme (Figure 11).
Together, the biochemical data for cytosolic V1 fractions of both
compound and single heterozygous mutants added insight to the biochemical
basis of our mutant phenotypes.

Genome-wide application of results

In all cases studied, a vma13Δ x vma3Δ compound heterozygous mutant
showed a worse growth phenotype relative to a single vma13Δ compound
heterozygous mutant. This included a significantly reduced growth at pH5,
normally an optimal condition to vma mutants. The unique quality of Vma3p
being a Vo subunit compared to the other V1 protein reductions studied in tandem
with a vma13 heterozygous deletion posed an interesting possibility because of
the potential effects on enzyme assembly and regulation. Since reduction of Vo
subunits potentially leaves fewer sites for the V1 region of the enzyme complex to
attach at the vacuolar membrane, the possibility existed that a heterozygous
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VMA3 deletion influenced the levels of free V1 in a cell. Free V1 levels are an
important variable given the VMA13 protein’s (H subunit) role in inactivating
these complexes [28]. On top of this possibility, biochemical analysis of mutant
cytosols, offered the possibility that a heterozygous Vo subunit mutation in
tandem with that of VMA13 could lead to a gain in activity of free V1 complexes
(Table 2).
Given the potential trend for compound vma13Δ and Vo subunit deletion
heterozygous diploids to have severe growth phenotypes, we decided to assay
additional combinations of compound vma13Δ and Vo subunit deletion
heterozygous diploids to expand our findings, this growth assay is shown in
Figure 12. In Figure 12, heterozygous diploid strains were constructed by crossing
a vma13Δ haploid containing a complementing VMA13 plasmid to a second
mutant haploid strain. Diploids were then streaked onto media with 5-fluoroorotic
acid (5FOA). Since 5FOA is lethal in the presence of the VMA13 plasmid URA3
marker, this media will not allow complemented heterozygous diploid strains to
maintain plasmid and selects for plasmid loss. Directly comparing growth in the
presence of 5FOA and in its absence, allows comparison of how plasmid loss (and
VMA13 copy reduction) affects cell growth. This is a crude assay because it is
difficult to streak exactly equal amounts of cells, however it is beneficial in its
ability to assay the effects of haploinsufficiency before they are overcome by
compensation mechanisms which permeate cell populations with severe defects
with the enzyme, problems we have had in the past with these unstable compound
heterozygous diploid strains (See Methods).
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As seen in Figure 12, single heterozygous vma13Δ strains showed a
significant reduction in growth upon plasmid loss. The growth of heterozygous
vma13Δ strains on 5FOA consisted of only a few small colonies spaced out
towards the center of the plate. Since yeast divide at an incredible rate, these few
colonies most likely represent a subpopulation of compensated mutants that
somehow managed to evolve a way to alleviate their defects (via chromosome
duplication, homologous recombination, ect.). While some areas of more dense
growth are seen in the heterozygous vma13Δ strain upon plasmid loss, it should
be noted that these regions are near the beginning of the streak and are most likely
due to an extremely large number of cells plated in that area (which would
provide even more compensated mutants). Therefore, the best estimate of the
effects of plasmid loss in this 5FOA assay is by comparing growth on 5FOA away
from the initial streak where a region of lower cell density was streaked (toward
the center of the plate).
In addition to the growth defects of a single heterozygous vma13Δ mutant
upon loss of VMA13 plasmid, more exacerbated phenotypes were seen for
vma13Δ x vma3Δ mutants as well as for vma13Δ heterozygotes compounded to
heterozygous mutations in Vo subunits (Figure 12). As evidenced by the growth
of less compensated colonies away from the initial streak as well as a thinner
growth surrounding the initial streak, it is clear that vma13Δ x vma3Δ mutants
have a hard time surviving upon plasmid loss and that their growth phenotypes
are more severe than a single vma13Δ heterozygote. Along these same lines,
analysis of vma13Δ x vma9Δ, vma13Δ x vph1Δ, and vma13Δ x stv1Δ also
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showed thinner growth on 5FOA, growing worse than single vma13Δ
heterozygous mutants but somewhat better than a vma13Δ x vma3Δ mutant. It
should be noted however, that, of the additional Vo subunit heterozygous
mutations compounded to that of vma13Δ, a heterozygous stv1Δ had the most
severe phenotype, showing no compensated colonies and only negligible growth
in its initial streak (Figure 12).
Taking into account the results from our 5FOA growth assays, which
supported the biochemical findings that a reduction of Vo subunits in tandem with
that of VMA13 can lead to an increase in free V1 activity in the cytosol, we
decided to look for new players in our biochemical scheme on a larger scale. By
implementing a genomic screen for potential gene reductions (in combination
with a reduction in VMA13 gene copy) which could lead to more active free V1,
or simply a greater V1 population that could confer this activity, we hoped to
elucidate new pathways of cross-talk, regulation, etc. for our beloved enzyme.
The screen was conducted as described in the Methods section and Figure
14, using a vma13Δ haploid strain with VMA13 plasmid complementation and
looked for phenotypes upon plasmid (VMA13 copy) loss. Through the use of an
electronically operated robot, a plasmid complemented vma13Δ strain was mated
to every library deletion (of opposite mating type) and compound heterozygous
diploid mutants were selected by antibiotic resistance (Figure 12). By selecting
for heterozygous diploids with antibiotic resistance, the screen assumes that cells
in need of an additional copy of VMA13 (those that are worse without it) will
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keep the plasmid. This selection was used in place of the typical auxotrophic
markers plasmid selection often entails.
Upon selection of plasmid complemented compound heterozygous diploid
strains (all of which have one heterozygous mutation for VMA13), the robot then
proceeds to pin these cells onto diploid selective media with and without 5FOA to
identify the effects, if any, of VMA13 plasmid loss. As described in Figure 13, a
“hit” for this screen would be a cell that shows growth on diploid selection media
without 5FOA but subsequently little or no growth in the presence of 5FOA.
Often times some compound heterozygotes failed to grow on diploid selection
media (without 5FOA) and these mutants cannot be identified as being
haploinsufficient with VMA13.
Given its layout (Figure 13), our genomic screen looked only for
heterozygous mutations in library genes for those genes that showed compound
haploinsufficiencies with VMA13. Similar to a compounded heterozygous VMA3
deletion, we anticipated that these strains would have synergistic effects when
reduced in tandem with VMA13, whether that be by means of increasing the
activity of free V1, increasing the amount of free V1, or through other unknown
mechanisms.
Of the 4800 library mutants we screened, 24 came up as repeatable hits in
our assay. Since we did the screen three independent times, any combination of
heterozygous mutations that was a hit twice was considered a true hit. These
double hits are listed in Table Three. Of the 24 genes, 8 were dubious and/or
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uncharacterized, lending little previous knowledge to their potential function, but
offering new possibilities for their study in relation to the V-ATPase enzyme.
Of the previously characterized hits, several were from overlapping or
common pathways. Among the interesting commonalities were the genes SSK1
and PTP2, both of which have been shown to be involved in the HOG pathway
and response to oxidative stress. Equally interesting was VID28, involved in
degradation of fructose-1,6-bisphosphatase, and GAL10, a glucose-epimerase,
given their close relationship to glucose, a known extracellular cue for the VATPase [1,2].
Besides these hits, several other membrane proteins and protein kinases
were among genes we identified with our screen. Eighteen of the twenty-four
initial hits were selected, on the basis of ontological function and overall
characterization of each ORF, and subjected to the same +/- 5FOA growth assay
as described previously (Figure 12). All of the hits showed various strengths
under this assay, intended to duplicate the results of our screen, with phenotypes
ranging from a mild reduction in growth upon VMA13 plasmid loss, which was
the case for uncharacterized or dubious ORFs YIL161W, YGL260W, and
YIL064W, to severe reductions in growth, which was the case for genes such as
SSK1, SLG1, and NGR1.
Because of our initial results, we decided to follow up on the strongest hits
first and/or those from interesting pathways (Figure 14). Of the ORFs showing the
strongest compound haploinsufficient phenotypes with VMA13 initially were
MUD1, SSK1, DYN3, SLG1 NGR1, LAG2, and several others not shown in
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Figure 14. Different from Figure 14, Figure 15 shows streaking over a much
larger surface area allowing cells to thin out and avoiding the complications of a
heavy streak. As mentioned previously, too heavy of a streak would provide many
cells capable of compensating their genetic defects. Because of this, a good
estimate of a strain’s health upon VMA13 plasmid loss is comparing cell growth
away from the streak on a larger surface area that has been streaked because this
assures fewer cells are spread there and less compensated mutants will come up.
Unlike Figure 14 which used small surface areas to accommodate many streaks,
the media used in Figure 15 allowed for a larger surface area and better analysis
of growth.
As shown in Figure 15, all of the stronger hits from Figure 14 as well as
those from pathways of interest, showed incredibly strong phenotypes after 48 hrs
of growth on 5FOA media. Upon plasmid loss, all of the compound heterozygous
strains streaked in Figure 15 showed negligible growth compared to that of
VMA13 complemented strains during the same time span. Together these results
confirm that our screen produced accurate, and duplicated, results. With the story
of haploinsufficiency for the V-ATPase becoming clearer, we will be certain to
follow up on these hits with more thorough biochemical analysis in the not-sodistant future.
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Discussion

Haploinsufficiency is defined as a dominant phenotype in diploid
organisms that are heterozygous for a loss-of-function allele [41]. Given the ease
of genetic manipulation in yeast, their stable life-cycle in both haploid and diploid
states, and the previously documented dosage sensitivities of the V-ATPase
enzyme [30, 31], a happloinsufficiency study on VMA genes was an obvious
choice.
Past studied have estimated that approximately 3% or more of the yeast
genome tests positive for haploinsufficient growth on YPD media [41]. While
YPD media is just one of an endless possibility for haploinsufficiency selections,
results suggest that the primary mechanism of haploinsufficiency in yeast is due
to insufficient protein production and also that haploinsufficiency commonly
affects multi-subunit complexes such as the ribosome [41].
In this study, we’ve identified a clear haploinsufficiency for the VMA13
gene (encoding subunit H). Initially manifested as a growth defect at elevated pH
and/or in the presence of extracellular calcium, haploinsufficiency of the VMA13
gene proved to have more profound biological implications on the cell, reducing
vacuolar acidification in vivo, reducing ATPase activity at the vacuole, causing an
apparent uncoupling of proton transport and ATP hydrolysis upon vacuole
isolation, and allowing for ATP hydrolysis in free V1 complexes in the
cytoplasm. Given the importance of VMA13 gene product as both a peripheral
stalk protein [2] and structural/functional regulator of the enzyme [29], its dosage
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sensitivity was not completely unexpected. The VMA13 gene’s sensitivity to
underexpression and both the growth and biochemical phenotypes of a
heterozygous vma13Δ mutant paralleled those of a haploid vma13Δ mutant [2830] and stood as a novel result.
After crossing vma13Δ mutants to various vma knockouts, we found
altered phenotypes of compound haploinsufficiencies for the enzyme which
helped, in part, to identify the underlying biochemical basis for VMA13’s
haploinsufficiency. Creating an imbalance of both subunits H (Vma13p) and c
(Vma3p) exacerbated haploinsufficiency phenotypes of cells, slowing growth on
all media, eradicating in vivo acidification at the vacuole, removing ATPase
activity and proton pumping at the vacuole, increasing cytosolic ATPase activity,
and reducing overall enzyme stability and assembly at the vacuolar membrane. In
contrast to these results, altering the balance of both H and B subunits (Vma13p
and Vma2p respectively), led to mostly opposite results, improving cell growth,
increasing in vivo acidification at the vacuole, and increasing the overall stability
and assembly of the enzyme complex relative to both a vma13Δ x vma3Δ and
vma13Δ x wt strains.
Different from its opposite effects on V-ATPase assembly and stability, a
vma13Δ x vma2Δ strain was not able to increase specific ATPase activity at the
vacuole, compared to vma13Δ x wt strains. However, as a compound
heterozygous vma mutant, it showed significantly improved activity relative to
the vma13Δ x vma3Δ strain and its ability to couple proton translocation to ATP
hydrolysis was better than all heterozygous vma13Δ strains studied.
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Together, the subunit locations and phenotypes of compound
heterozygous vma mutants are explained, at least in part, by their biochemical
phenotypes observed in our analysis. A perturbation of H subunit stoichioimetry
creates a gain in ATPase activity in the stable population of free V1 sectors in the
cytoplasm and results in an uncoupling of ATP hydrolysis and proton
translocation, in essence wasting away intracellular energy stores. The wasting of
energy coincides with the poor growth of vma13Δ heterozygotes and, along the
same lines, the level and activity of this active free V1 population underlies many
phenotypic differences amongst compound heterozygous mutants. For instance, a
vma13Δ x vma3Δ strain has an increased activity in its free V1 population which
is an underlying force behind its exacerbated growth and biochemical phenotypes.
Contrasting this, a vma13Δ x vma2Δ strain has less ATPase activity in its free V1
population, contributing, at least partially, to this strain’s improved growth and
biochemical phenotypes.
While many compound mutant phenotypes can be explained, at least
partially, by this biochemical phenomenon, a reduction of ATPase activity at the
vacuole along with reduced V-ATPase assembly at the vacuole for some strains
(e.g. vma13Δ x vma3Δ heterozygotes) suggests that perturbation of certain
subunit levels may also have effects on overall enzyme stability and assembly.
The severe reduction in all subunit levels for a vma13Δ x vma3Δ strain stands as
an intriguing result, supporting the notion of synergistic effects for a compounded
heterozygous vma13 and vma3 deletions, but also suggests the possibility that
defects in overall enzyme biosynthesis may lead to the strain’s severe instability.
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Regardless of the cause behind a vma13Δ x vma3Δ strain’s defects at the
vacuole however, the cytosolic V1 fractions of this mutant are responsible for its
phenotypic differences from vma13Δ x wt strain. Because a vma13Δ x wt strain
shows uncoupling at the vacuolar membrane, its growth phenotypes should be not
be better than those seen in the vma13Δ x vma3Δ strain, comparing V-ATPases
at the vacuole alone, because a vma13Δ x vma3Δ strain has no ATPase activity
and no pumping, which is not as wasteful as an uncoupled enzyme. As a result,
the exacerbated growth phenotypes for a vma13Δ x vma3Δ strain relative to
vma13Δ x wt must be due to the strain’s more active cytosolic V1 complexes.
This population’s activity is clearly the differentiating factor between a vma13Δ x
vma3Δ strain and all other heterozygous VMA13 mutants. For this reason, we
can, at least in part, overlook defects in biosynthesis and/or assembling when
explaining our biochemical model of VMA13’s haploinsufficiency.
In addition to the ATPase activity of a vma13Δ x vma3Δ strain’s
cytosolic V1 complexes, is the relative amount of free V1 in this strain relative to
other heterozygous vma13 mutants. Given the status of the Vma3p as a Vo
subunit, the possibility exists that a Vo subunit reduction (such as that of Vma3p)
in tandem with that of VMA13 could lead the cell to produce a greater population
of free V1 relative to a single heterozygous vma13 deletion strain (without the
heterozygous Vo mutation). An increased population of free V1, in addition to its
already increased ATPase activity levels, would certainly be another factor
contributing to the synergistic phenotypes seen in all vma13Δ x heterozygous Vo
subunit deletion strains. This possibility however, remains to be explored.

46

In summary, this data sheds light onto subunits in the V-ATPase enzyme
normally present, in vivo, in limited quantities, highlighting their importance for
an active and healthy enzyme. From our analysis it is clear that the VMA13
subunit (H) is required at a precise dosage in order to form a functional V-ATPase
enzyme complex. Somehow, reducing the gene copy for VMA2 in tandem with
that of VMA13 seems to allow less active (assembled) enzyme complexes at the
vacuole, however those that are able to assemble, couple ATP hydrolysis to
proton translocation more efficiently. Contrasting this result, the synergistic
effects of a heterozygous vma3 deletion in tandem with that of VMA13, suggests
that reducing Vo subunit copy in tandem with VMA13 can cause cytosolic defects
for the enzyme’s free V1 complexes. This phenomenon introduced the possibility
of looking for new gene products which acted similarly, having synergistic effects
on overall enzyme activity and stability or increasing the amount and/or activity
of free V1 complexes.
From our genomic screen data, it is clear that several genes cause
phenotypic effects when reduced in copy alongside a VMA13 gene reduction.
While these results may or may not provide the specific phenotypes we’ve
characterized, they certainly shed light onto new proteins and pathways of interest
that influence the V-ATPase. Different from single haploinsufficiency studies, a
compound haploinsufficiency analysis represents a more common phenotypic
result in vivo, since for the approximately 97% of the yeast genome that does not
show haploinsufficiency in single heterozygotes, addition of a second
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heterozygous mutation may shed light onto previously mild/undocumented
phenotypes [41].
When dealing with the likelihood if haploinsufficiencies in vivo, it is
difficult to overlook to profound human relevancy of this genetic defect. Humans,
as higher diploid organisms, inherently have a susceptibility to
haploinsufficiency. While mutational models for most genetic diseases such as
cancer originally envisioned a two-hit mutational event in which both functional
copies of a gene must be lost to produce a phenotype, current research is
contradicting this model [42]. Current studies on tumor suppression and drugresistance suggest that haploinsufficient phenotypes are possible in humans for a
variety of genetic defects [42, 43]. In addition to this, current cancer research
additionally suggests that various combinations of altering only a limited number
of cellular pathways is sufficient enough to induce a cancerous phenotype in
normal cells [44].
Together, these results only cement the importance of our genetic study, as
the statistical likelihood of haploinsufficiency mutational events we’ve studied is
more likely than a two-hit loss of function model. In addition, our genomic
analysis of compound haploinsufficient mutants offers the possible alteration of
multiple pathways, again lending the possibility of phenotypic consequences in
genetic disease and elsewhere.
In conclusion, putting our results in context with this current research on
haploinsufficiency, it is increasingly possible that many genetic defects not
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already linked to a defective V-ATPase enzyme may be the result of V-ATPase
subunit haploinsufficiency in genes such as VMA13.

**Please note that this work will be submitted for a peer-reviewed scientific
journal publication (most likely the Journal of Biological Chemistry or EMBO
Journal) this summer. For further reference on this subject matter search
“Haploinsufficiency of the yeast VMA13 gene in simple and compound
heterozygotes” on NCBI’s PubMed database or contact Dr. Patricia Kane at
SUNY Upstate Medical University for the status of this pending publication
(kanepm@upstate.edu)**
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Figure 1: Subunit composition and structural model of the yeast V ATPase.
Figure and legend taken directly from Patricia M. Kane [2]. V1 subunits are
shown in pink and purple and V0 subunits are shown in green. A single stator
stalk containing subunits C, E, G, and H is shown, but recent electron microscopy
evidence suggests that there may be two peripheral stalks in the closely related
Neurospora crassa V-ATPase. If there are two stator stalks in the yeast enzyme, it
is likely that each stalk will contain subunits E and G, but one stalk may contain
subunit H, and the other subunit C.
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Figure 2: Overview of reversible disassembly of V-ATPase in yeast cells.
Figure and legend taken directly from Patricia M. Kane [2]. Intact, active VATPase complexes are rapidly disassembled into free V1 and V0 complexes in
response to glucose deprivation. Glucose readdition results in reassembly of the
V-ATPase, and is slow and incomplete in the absence of the RAVE complex.
RAVE binding to V1 is compromised in mutants lacking subunit E or G,
suggesting that these two subunits are involved in the interaction of V1 and
RAVE. Subunits that are believed to undergo major conformational changes
during disassembly are identified: the H subunit shifts from being an activator of
V1V0 complexes to being an inhibitor of free V1 complexes, the cytoplasmic Nterminal domain of the a subunit appears to fold down onto the rest of V0, and the
C subunit is released from both the V1 and the V0 sectors during disassembly.
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Figure 4: Growth phenotypes of single heteroyzgous vmaΔ mutants. Wild-type
yeast cells (bottom two rows) and heterozygous vmaΔ cell lines, as indicated,
were grown to log phase and equal amounts (~0.7-1 A600/ml) were subjected to
10-fold serial dilutions. Diluted cells were subsequently transeferred to a YEPD
plate buffered to pH 5, YEPD buffered to pH 7.5, or YEPD buffered to pH 7.5
containing 60 mM CaCl2. The growth of the strains was compared after 2-4 days
at 30C.
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Figure 5: Growth phenotypes of compound heteroyzgous mutants of vma3Δ.
Please refer to Figure 4 legend for explanation.
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Figure 6: Growth phenotypes of compound heteroyzgous mutants of
vma10Δ. Please refer to Figure 4 legend for explanation.
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Figure 7: Growth phenotypes of compound heteroyzgous mutants of
vma13Δ. Please refer to Figure 4 legend for explanation.
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Figure 8: Quinacrine uptake into vacuoles of wild-type, single, and compound
heterozygous vmaΔ mutant cells. All cell lines were incubated with the
lysosomotropic amine quinacrine stain for equal durations and visualized under
Nomarski optics (left panel of each two photo set) and fluorescence optics (right
panel of each set). All fluorescence images were exposed for identical times and
each set (A-F) is a representative sampling of the population of stained/unstained
vacuoles in that cell line.
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Figure 9: Levels of V—ATPase subunits in vacuoles from single and
compound heterozygous vmaΔ mutant cells. Vacuolar vesicles were isolated as
described in the Methods section. Vacuolar proteins were solubilized, separated
by SDS-PAGE, and transferred onto nitrocellulose membrane before probing with
V-ATPase subunit-specific monoclonal antibodies. A, immunoblot of vacuolar
vesicle proteins probed with antibodies to vacuolar protein Alkaline Phosphatase
(ALP), Vo subunit a, and V1 subunit C. 10µg of protein was loaded for
visualization of ALP proteins, 20µg was loaded for visualization of a and C
subunits. B, an immunoblot titration (2 and 5µg) of vacuolar vessicle proteins was
probed with antibodies to V1 subunit A and V1 subunit B.
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Figure 10: Proton pumping in vacuole vessicles for single and heterozygous
vmaΔ mutants. Equal amounts of vacuolar vesicles (~10 µg of protein per assay)
isolated from the indicated strains were mixed with 1 µM ACMA in transport
buffer (50 mM NaCl, 30 mM KCl, 20 mM HEPES, pH 7) in a fluorometer cuvette.
Fluorescence emission intensity was monitored continuously as the mixture was
stirred at 25 °C, and at the indicated point a mixture of MgSO4 and ATP was
added to give final concentrations of 1 mM MgSO4 and 0.5 mM ATP (indicated as
0.5 mM ATP on each plot). After the fluorescence decrease had stabilized, 100 nM
concanamycin A was added to the cuvette at the indicated time. Additionally, a
control experiment was conducted for each strain in which 100 nM concanamycin
A was present throughout the assay to inhibit any V-ATPase-dependent changes
in fluorescence. Different colors are used to indicate each specific strain’s
fluoresence plots (both experimental and control runs). These colors and their
respective strains/experiments are indicated on each Figure (A-C).
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Figure 11: Protein profiles of peak fractions from free V1 purification. The
isolated free V1 fractions collected from FLAG purification were analyzed for
specific ATPase activity using kinetic assays. The protein content and purity of
each cell line’s peak fraction (that showing the most activity) was further studied.
A. 20µg of each peak fraction’s protein was subjected to SDS-PAGE and fixed
using Coomasie Brilliant Blue Dye. B, Despite their similar protein profiles, peak
fractions were also probed specifically for V1 subunits (A & B) to further to
further confirm that V1 proteins were among those in peak fractions. C, Different
from all other strains, the vma13Δ x vma3Δ strain was precipated using 100%
TCA and showed a more obvious protein composition, with easily identifiable V1
subunits upon SDS-PAGE and fixation with Coomasie Blue. Since the entire
fraction was precipitated, we could not probe for V1 subunits. Future experiments
will address this.
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Figure 12: Growth phenotypes upon direct VMA13 plasmid loss for vma13Δ
x Vo subunitΔ mutants. Cell lines were cultured on SC +G418 +Nat plates and
colonies of approximately equal size were then struck onto both SC +G418 +Nat
and SC +G418 +Nat +5FOA for comparison. Pictures were taken after 48 hours
of growth. Since 5FOA is lethal in the presence of the VMA13 plasmid URA3
marker, this media does not allow complemented heterozgous diploid strains to
maintain plasmid and selects for plasmid loss. Directly comparing growth in the
presence of 5FOA and in its absence, allows a direct comparison of how plasmid
loss (and VMA13 copy reduction) affects cell growth.
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Figure 14: Growth phenotypes upon direct VMA13 plasmid loss for genomic
screen hits. Please refer to Figure 12 legend for explanation.
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Figure 15 (A & B): Growth phenotypes upon direct VMA13 plasmid loss
confirmed genomic screen hits. Please refer to Figure 13 legend for explanation.
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